Linked Life Data

20667515

Source:http://linkedlifedata.com/resource/pubmed/id/20667515

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2010-9-24
pubmed:abstractText
Biologics including tumor necrosis factor ? (TNF-?), interleukin-6 receptor (IL-6R), T and B cell inhibitors are very effective therapeutic agents for the treatment of arthritides. These compounds effectively improve articular symptoms and inhibit joint damage. In this respect, there are no major differences in the efficacy of the available biologics. However, many arthritis patients also exert extra-articular features, systemic manifestations of the disease. These associated conditions include uveitis, inflammatory bowel disease, psoriasis, secondary bone loss and cardiovascular disease. There have been data suggesting that there may be differences in the effects of various TNF inhibitors, rituximab and tocilizumab on the systemic manifestations described above. At present, we do not always have sufficient evidence to confirm these differences, therefore, more information should be obtained from large trials and long-term observational studies.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1873-0183
pubmed:author
pubmed:copyrightInfo
Copyright © 2010 Elsevier B.V. All rights reserved.
pubmed:issnType
Electronic
pubmed:volume
9
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
820-4
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Biologics - beyond the joints.
pubmed:affiliation
Department of Rheumatology, Institute of Medicine, University of Debrecen Medical and Health Science Center, Hungary. szekanecz.zoltan@med.unideb.hu
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't